Why has there been a dramatic decline in pediatric epiglottitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

The Dramatic Decline in Pediatric Epiglottitis

The dramatic decline in pediatric epiglottitis is directly attributable to the introduction and widespread implementation of Haemophilus influenzae type b (Hib) conjugate vaccines, which began in the United States in 1987-1989 and resulted in a 99% reduction in invasive Hib disease by 2000. 1

The Pre-Vaccine Era

Before 1985, Haemophilus influenzae type b was the leading cause of bacterial meningitis and a common cause of epiglottitis among U.S. children aged <5 years. 1 Epiglottitis was a frequent and life-threatening manifestation of invasive Hib disease, with approximately 4% of all invasive Hib cases being fatal. 1

The Vaccine Revolution

Timeline of Vaccine Introduction

  • 1985: First polysaccharide Hib vaccine introduced in the United States 1
  • 1987-1989: Conjugate Hib vaccines licensed, which were far more effective than polysaccharide vaccines 1
  • 1990: Conjugate vaccines licensed for use in infants 1

Mechanism of Protection

The conjugate vaccines work by linking the PRP polysaccharide with protein carriers, which confers T-lymphocyte-dependent characteristics to the vaccine. 1 This conjugation enhances the immunologic response to the PRP antigen, particularly in young infants, and results in immunologic memory. 1

The Epidemiologic Impact

Magnitude of Decline

During 1989-2000, the annual incidence of invasive Hib disease in children aged <5 years decreased by 99%, to less than one case per 100,000 children. 1 This dramatic reduction directly translated to the near-disappearance of pediatric epiglottitis.

Real-World Evidence

  • Finland (1985-1992): With vaccination coverage of 94-98% of infants, Hib epiglottitis cases decreased from 50-60 cases annually in 1985-1986 to only 2 cases in 1992. 2
  • United States (1979-1992): The average annual incidence of epiglottitis declined from 10.9 per 10,000 admissions before 1990 to 1.8 per 10,000 admissions from 1990-1992. 3
  • United Kingdom (1992-2001): A sharp decline in cases occurred after the Hib vaccine was introduced in October 1992. 4

Herd Immunity Effect

Vaccination with Hib conjugate vaccine leads to decreases in oropharyngeal colonization among both vaccinated and unvaccinated children. 1 The prevalence of Hib carriage has decreased among preschool-aged children from 2-7% in the prevaccine era to <1% in the vaccine era. 1

Changes in Disease Characteristics

Age Shift

The median age of children with epiglottitis increased from 35.5 months in the pre-vaccine era to 80.5 months in the post-vaccine era. 3 This reflects the fact that most cases now occur in older, unvaccinated children or those with vaccine failure.

Pathogen Shift

Hib was identified as the causative organism in 76% of epiglottitis cases before 1990, but in only 25% of cases from 1990-1992. 3 Group A beta-hemolytic streptococcus and other pathogens have emerged as alternative causes in the post-vaccine era. 3, 4

Current Vaccination Recommendations

The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination with a licensed conjugate Hib vaccine for infants aged 2 through 6 months (2 or 3 doses, depending on vaccine product) with a booster dose at age 12 through 15 months. 1

High-Risk Populations Requiring Special Attention

  • American Indian/Alaska Native infants should receive a 2-dose primary series of PRP-OMP vaccine (PedvaxHIB or Comvax) for early protection, as Hib meningitis peaks at a younger age (4-6 months) in this population. 1
  • Children with immunocompromising conditions (functional or anatomic asplenia, HIV infection, immunoglobulin deficiency, early component complement deficiency, hematopoietic stem cell transplant recipients, or those receiving chemotherapy) require vaccination regardless of age. 1

Important Clinical Caveats

Vaccine Failure

While rare, vaccine failure does occur. In one UK series, 20% of epiglottitis cases presented after vaccine introduction, with four of five post-vaccine Hib cases occurring in fully vaccinated children. 5 Children who develop Hib disease despite appropriate vaccination should be evaluated for immunological deficiency. 1

Continued Vigilance Required

Despite the dramatic decline, epiglottitis has not completely disappeared. 6 Recent epidemiologic data show a decrease in incidence with a shift toward older patients. 6 Clinicians must maintain awareness of this diagnosis, particularly as fewer physicians will have experience recognizing the disease. 5

Current Epidemiology

During 2000-2012, the average annual incidence rate of invasive Hib disease in children aged <5 years in the United States remained below the Healthy People 2020 goal of 0.27/100,000. 1 Most cases now occur in underimmunized infants and children or those too young to have completed the primary immunization series. 1

References

5
Research

Paediatric acute epiglottitis: not a disappearing entity.

International journal of pediatric otorhinolaryngology, 2003

6
Research

Croup and Epiglottitis.

Pediatrics in review, 2025

Related Questions

What is the prehospital treatment for epiglottitis at the paramedic (Emergency Medical Technician) level?
What diagnostic imaging modalities are used to confirm epiglottitis, and what additional tests are indicated?
In a 13-year-old male with suspected epiglottitis, what immediate actions (such as obtaining IV access, drawing blood cultures, administering empiric antibiotics and steroids) should be taken in addition to supportive care and airway observation before transfer to the emergency department?
What is the most common cause of hemorrhagic epiglottitis?
How should I evaluate and manage a patient with a blood pressure of 122/77 mm Hg and a heart rate of 123 beats per minute (tachycardia)?
What is the recommended vancomycin steady‑state trough concentration and dosing regimen for bacterial meningitis?
What are the recommended cephalexin dosing guidelines for adults, children, patients with renal impairment, and those with penicillin allergy?
Which lumbar spine X‑ray views are appropriate for evaluating lower back pain?
Does poor R‑wave progression on a 12‑lead ECG indicate prior ischemic injury or an active myocardial infection (myocarditis)?
How should mild lower leg swelling be documented in the medical record?
What is the appropriate management of warfarin (Coumadin) for a patient with a history of deep‑vein thrombosis undergoing colonoscopy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.